In Brief: LXN Corp.
This article was originally published in The Gray Sheet
Executive Summary
LXN Corp.: San Diego-based firm plans to launch its Duet glucose control monitoring system in January following 510(k) clearance in October. The system combines on one hand-held meter two fingerstick tests, an eight-second blood glucose test and a four-minute glycated protein (fructosamine) test. In addition to direct-to-consumer sales, the firm expects "to aggressively market" the system as an in-office test to healthcare professionals...
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.